SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details:Poster Title: Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trialPresenter: Wen-Wei Tsai, Ph.D.,...

— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —  RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution in its strategy to build value through development and commercialization of rare disease therapies. Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Development Officer, overseeing global clinical development and safety across a broad portfolio spanning multiple therapeutic areas. Under his leadership,...

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Ontario, April 06, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX: MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced that senior management will host a conference call on Tuesday, May 5, 2026 at 8:30 a.m. ET to discuss the REIT’s first quarter 2026 results. First Quarter 2026 Results Conference Call and WebcastDATE: Tuesday, May 5, 2026TIME: 8:30 a.m. ETINSTANT JOIN BY PHONE: Conference Call Registration (Click the URL to join the conference call by phone)Please register at least 10 minutes before the start of the call. Upon registration, an email will be sent, including dial-in details and a unique conference call access code required to join the live call.LIVE WEBCAST:Q1 2026...

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build...

– Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment – – Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year – – Current cash of approximately $100 million now extends cash runway into 2029, through expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers – – Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1 remain on track for mid-2026 – RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics”, “Opus”, or the “Company”),...

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory review. NRx previously received a preliminary determination of bioequivalence for this product. The Company continues to anticipate a decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026.WILMINGTON, Del., April 06, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has received a letter from the Labeling Program of the FDA Office of Generic Drugs whose only comments were limited to minor formatting changes to the proposed label for the Company’s preservative-free ketamine product. The Company expects to submit the...

WINNIPEG, Manitoba, April 06, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI or the Company) a leading manufacturer of buses and coaches and a provider of comprehensive aftermarket parts and service solutions, today announced the release date of its first quarter of 2026 (Q1 2026) financial results and notes that the Company’s Board of Directors (Board) has set the date for its Annual and Special Meeting of Shareholders for May 8, 2026 at 11:00 a.m. Eastern Time (ET). First Quarter 2026 Results Release NFI intends to release its Q1 2026 financial results on Thursday, May 7, 2026, after market close with a conference call and webcast to discuss the results on Friday, May 8, 2026, at 8:30 a.m. ET. For attendees who wish to join by webcast, registration is not required; the event can be accessed at...

SOMERSET, N.J., April 06, 2026 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leading provider of healthcare technology and AI-enabled revenue cycle management (“RCM”) solutions, today announced a new partnership with Arkansas Otolaryngology Center, P.A., one of the region’s most respected Ear, Nose, Throat, Allergy, and Sleep practices. Based in Little Rock, the multi-location practice has selected CareCloud’s AI-powered practice management and revenue cycle management solutions to streamline operations, accelerate revenue capture, and elevate the patient experience across Arkansas. “We are thrilled to partner with CareCloud as we enhance our practice management system and RCM operations,” said Jelinda Scott, Chief Administrative Officer of Arkansas Otolaryngology Center. “Their technology...